Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new contract with the Institute of Immunology and Genetics (‘IIG’ or the ‘Institute’) a leading molecular genetic laboratory in Kaiserslautern, Germany, equipped with state-of-the-art equipment and comprehensive human genetic and bioinformatic expertise.
From analysis of established gene variants, through next generation sequencing (NGS) panel analysis of disease genes, to whole exome analysis of the entire genome, the IIG provides a full range of molecular genetic diagnostics with particular focus on diagnostics for hereditary diseases and anomalies during pregnancy.
The Congenica clinical decision support platform will be used by IIG to evaluate gene panels and whole exomes with greater precision and speed, enabling the Institute’s critical work in prenatal diagnostics to provide accurate life-changing answers with greater efficiency to more patients in Germany.
Dr Anne-Karin Kahlert, Institute of Immunology and Genetics in Kaiserslautern, said: “Congenica’s technology stands out as delivering rapid and highly accurate interpretation of genetic variants, enabling a genetic diagnosis in a very short time for targeted and therapy-relevant questions. This is of paramount importance to us in genetic diagnostics, especially for prenatal cases, which are a particular area of focus for us. The Congenica platform will allow us to dramatically reduce turnaround times in the diagnostic process, which will be of great benefit to our patients.”
Freddie Sharkey, PhD, VP of Sales EMEA, Congenica, said: “This partnership with the Kaiserslautern Institute of Immunology and Genetics enables us to extend our foothold in the strategically important region and its surrounding territories. We look forward to supporting the Institute with their whole exome sequencing service, using our proprietary market leading genomic analysis technology.”
About Institute of Immunology and Genetics
The Institute of Immunology and Genetics (‘IIG’) was founded in 1997 and is a completely independent medium-sized company in Kaiserslautern. The institute is a regional and supra-regional service provider for physicians in private practice, specialized treatment centres, hospitals, university research institutes, stem cell donor organizations, companies in the research-based pharmaceutical industry in Germany, Europe and overseas, as well as for courts and youth welfare offices in the context of parentage assessments.
The specialist focus is based on the highest technological expertise with the competence for in-house development of molecular biological tests on state-of-the-art sequencing platforms in a group of molecular biologists, bioinformaticians, virologists, human geneticists, pathologists and laboratory physicians.
Beyond diagnostics, Institute staff advise physicians to ensure optimal therapy for their patients.
Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that will in future improve wellbeing and disease management.
Congenica’s world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
For more information visit www.congenica.com.
Contact details for enquiries
Commercial Director DACH – Germany, Austria & Switzerland
Institut für Immunologie und Genetik
Bernhard Thiele, Anne-Karin Kahlert, Frank Glaab
Tel: +49 (0)631 316700
Consilium Strategic Communications
Chris Gardner, Angela Gray, David Daley
Tel: +44 (0)20 3709 5700